B Cell Repertoire Molecular Platform for Antibody Drug Discovery

用于抗体药物发现的 B 细胞库分子平台

基本信息

  • 批准号:
    8756836
  • 负责人:
  • 金额:
    $ 24.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Specific Aim of this Innovative Molecular Analysis Technologies (IMAT) SBIR Phase I grant proposal is to show the feasibility of a high-throughput molecular technology for discovery of monoclonal antibody (mAb) drugs for oncology from human B cell repertoires. Drug companies spend up to $5 billion to produce a single FDA-approved monoclonal antibody, or mAb (DiMasi & Grabowski, 2007; Nelson et al., 2010). High mAb development cost is at least partly due to the high failure rate of candidates. A technology that improves mAb selection by just 10% before entering clinical development could save the drug industry ~$400 million per FDA- approved mAb. Immune systems are "test tubes" that constantly select for antibodies with strong potential as drugs. GigaLink" will be a research service for drug discovery programs that leverages these antibody selection test tubes. In mouse systems, our technology could eventually replace B cell immortalization. In human systems, our technology could eventually replace phage display. Antibody fragments identified in our DNA libraries will be easily modified into mAbs, because they are fully human, are already known to express on the surface of B cells, and have already shown positive selection in vivo. In Phase I we will integrate our current molecular and bioinformatic methods with mammalian expression and affinity screening. The project will focus on antibody fragments against epidermal growth factor receptor (EGFR), because many anti-EGFR biologics are available to help us test our system. Though we focus on EGFR, the primary outcome of this project is platform development - ideal for the IMAT program at the National Cancer Institute (NCI). We will accomplish the Specific Aim by performing the following tasks: (i) Optimize mammalian expression and affinity screening using known anti-EGFR antibody fragments; (ii) Implement computational methods for quantitatively integrating genomic and affinity data; and (iii) Screen pancreatic cancer patient B cells for anti-EGFR antibody fragments. To be successful, we must achieve the following metrics: (i) Recover >80% of known anti-EGFR antibody fragments by mammalian expression and affinity screening (power=0.8, ¿=0.05); and (ii) Use germline divergence rates and affinity screening to discover no less than ten anti-EGFR antibody fragments with affinity constant (Kaff)<10-7 and significant sequence evolution rates (power=0.8,¿=0.05). In Phase II, we will focus on laboratory and computational methods for affinity maturation of fully human monoclonal antibodies from GigaLink" antibody fragments. Once Phase II is complete, GigaGen will compete directly with mAb discovery services such as Morphosys and Adimab. Future grant applications will focus on oncology targets for discovery and development of GigaGen-proprietary drugs for pancreatic cancer targets (Dodson et al., 2011), but this will only be possible once the current IMAT project has been completed.
描述(由申请人提供):这项创新的分子分析技术(IMAT)SBIR第一阶段资助提案的具体目的是展示高通量分子技术的可行性,以从人类B细胞库中发现用于肿瘤的单抗(MAb)药物。制药公司花费高达50亿美元来生产FDA批准的单一单抗或单抗(DiMasi&Grabowski,2007;Nelson等人,2010)。MAb研发成本高至少部分是由于候选抗体的高失败率。一项在进入临床开发之前仅将单抗选择提高10%的技术可以为制药业节省约4亿美元,每单抗经FDA批准。免疫系统是“试管”,不断地挑选具有强大药物潜力的抗体。GigaLink“将是利用这些抗体选择试管的药物发现项目的研究服务。在小鼠系统中,我们的技术最终可能取代B细胞永生化。在人类系统中,我们的技术最终可能取代噬菌体展示。在我们的DNA文库中鉴定的抗体片段很容易被修饰成单抗,因为它们完全是人类的,已经知道在B细胞表面表达,并且已经在体内显示出阳性选择。在第一阶段,我们将把我们目前的分子和生物信息学方法与哺乳动物表达和亲和力筛选相结合。该项目将专注于针对表皮生长因子受体(EGFR)的抗体片段,因为许多抗EGFR的生物制品可以帮助我们测试我们的系统。虽然我们专注于EGFR,但该项目的主要成果是平台开发--这是美国国家癌症研究所(NCI)IMAT项目的理想选择。我们将通过执行以下任务来实现这一特定目标:(I)使用已知的抗EGFR抗体片段优化哺乳动物的表达和亲和力筛选;(Ii)实施量化整合基因组和亲和力数据的计算方法;以及(Iii)筛选胰腺癌患者B细胞中的抗EGFR抗体片段。为了获得成功,我们必须达到以下指标:(I)通过哺乳动物表达和亲和筛选(POWER=0.8,?=0.05)回收80%的已知抗EGFR抗体片段;以及(Ii)使用种系离散率和亲和筛选,发现不少于10个亲和常数(Kaff)&lt;10-7和显著序列进化速率(POWER=0.8,?=0.05)的抗EGFR抗体片段。在第二阶段,我们将重点研究从GigaLink抗体片段中亲和成熟全人类单抗的实验室和计算方法。一旦第二阶段完成,GigaGen将直接与单抗发现服务,如Morphosys和Adimab竞争。未来的赠款申请将侧重于发现和开发用于胰腺癌靶点的GigaGen专有药物的肿瘤学目标(Dodson等人,2011年),但这只有在当前的IMAT项目完成后才可能实现。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Scott Johnson其他文献

David Scott Johnson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Scott Johnson', 18)}}的其他基金

Commercialization of an Advanced Technology for T Cell Receptor Analysis and Engineering
T 细胞受体分析和工程先进技术的商业化
  • 批准号:
    9193662
  • 财政年份:
    2016
  • 资助金额:
    $ 24.91万
  • 项目类别:
Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency
重组超免疫丙种球蛋白治疗原发性免疫缺陷
  • 批准号:
    9139000
  • 财政年份:
    2016
  • 资助金额:
    $ 24.91万
  • 项目类别:
Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency
重组超免疫丙种球蛋白治疗原发性免疫缺陷
  • 批准号:
    9304957
  • 财政年份:
    2016
  • 资助金额:
    $ 24.91万
  • 项目类别:
Production Technology for Recombinant Intravenous Immunoglobulin
重组静脉免疫球蛋白生产技术
  • 批准号:
    8976337
  • 财政年份:
    2015
  • 资助金额:
    $ 24.91万
  • 项目类别:
Recombinant Hyperimmune Gammaglobulin for Pneumococcal Disease
用于治疗肺炎球菌疾病的重组超免疫丙种球蛋白
  • 批准号:
    8979450
  • 财政年份:
    2015
  • 资助金额:
    $ 24.91万
  • 项目类别:
Next-Generation Antibody Discovery and Development Technology
下一代抗体发现和开发技术
  • 批准号:
    9174883
  • 财政年份:
    2014
  • 资助金额:
    $ 24.91万
  • 项目类别:
Therapeutic Antibody Discovery from Pancreatic Cancer B Cell Repertoires
从胰腺癌 B 细胞库中发现治疗性抗体
  • 批准号:
    8832750
  • 财政年份:
    2014
  • 资助金额:
    $ 24.91万
  • 项目类别:
Cloud-Based Bioinformatics for Immune Repertoire Analysis
用于免疫谱分析的基于云的生物信息学
  • 批准号:
    8642691
  • 财政年份:
    2012
  • 资助金额:
    $ 24.91万
  • 项目类别:
Massively Parallel Haplotyping
大规模平行单倍型分析
  • 批准号:
    8198444
  • 财政年份:
    2012
  • 资助金额:
    $ 24.91万
  • 项目类别:
Cloud-Based Analysis of TCR Repertoire Sequencing Data
基于云的 TCR 谱库测序数据分析
  • 批准号:
    8394673
  • 财政年份:
    2012
  • 资助金额:
    $ 24.91万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 24.91万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了